NASDAQ:MYGN
Myriad Genetics Inc.
Myriad Genetics Inc.'s revenue fell 1.6% in fiscal 2025 to $824.5M while operating margin fell to −47.0%. The diluted share count rose 2.2%.Summary generated from Myriad Genetics Inc.'s SEC filings. Latest annual report filed Feb 24, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$824.5M
Revenue growth−1.6%
Revenue, 5-yr CAGR+8.2%
Gross margin69.9%
Operating margin−47.0%
Net margin−44.4%
ROIC−62.6%
Return on equity−68.5%
Debt / equity0.33
Free cash flown/a
FCF marginn/a
Share count change+2.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 691 | 678 | 753 | 838 | 825 |
| Operating income | −191 | −141 | −257 | −124 | −387 |
| Net income | −27 | −112 | −263 | −127 | −366 |
| Free cash flow | 1 | −152 | n/a | n/a | n/a |
Recent filings
- 8-KDirector or officer change
Oct 9, 2026 - 4Insider transaction report
Sep 22, 2026 - 4Insider transaction report
Sep 18, 2026 - 8-KDirector or officer change
Sep 16, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 31, 2026 - 8-KResults of operations and financial condition
Jul 30, 2026 - 8-KDirector or officer change
Jun 23, 2026 - 8-KDirector or officer change
Jun 4, 2026